What Happened
- A recent analysis examined India's growing potential to drive the next major global breakthrough in cancer treatment and research, highlighting the country's expanding research ecosystem, clinical infrastructure, and indigenous biotech capabilities.
- India's first homegrown CAR-T cell therapy, NexCAR19, developed by IIT Bombay, Tata Memorial Centre, and ImmunoACT, received market authorisation from India's Central Drugs Standard Control Organisation (CDSCO) in October 2023 and was formally launched by the President of India in April 2024.
- NexCAR19 is priced at approximately ₹40 lakh (~$50,000), roughly one-tenth the cost of comparable therapies in the United States (~$400,000), making cutting-edge cancer immunotherapy accessible at scale.
- India's National Cancer Registry Programme (ICMR-NCRP) projects approximately 1.57 million new cancer cases in India for 2025, underscoring the urgency of indigenous treatment development.
Static Topic Bridges
CAR-T Cell Therapy — Mechanism and Significance
CAR-T (Chimeric Antigen Receptor T-cell) therapy is a form of personalised immunotherapy in which a patient's own T-cells are extracted, genetically engineered to express synthetic receptors that recognise cancer-specific antigens, expanded in a laboratory, and reinfused into the patient to attack tumour cells. It represents a paradigm shift in oncology — moving from broad-spectrum chemotherapy and radiation toward precision, cell-based therapies that harness the immune system. CAR-T therapy has shown remarkable efficacy against certain blood cancers (lymphoma, leukaemia, multiple myeloma) that are otherwise resistant to conventional treatment.
- NexCAR19 targets CD19, a protein expressed on B-cell cancers (lymphoma and leukaemia).
- In Indian clinical trials (64 patients), 67% achieved objective response; approximately 50% achieved complete remission.
- India's second approved CAR-T therapy is Qartemi (by Immuneel Therapeutics) for B-cell Non-Hodgkin Lymphoma.
- A key innovation in NexCAR19 is its "humanised" antibody design, which reduces cytokine release syndrome — a dangerous immune overreaction seen with earlier CAR-T therapies.
- Cost advantage: Indian CAR-T therapy costs ~6% of Western equivalents, democratising access.
Connection to this news: NexCAR19 demonstrates India's ability to move from research labs to regulated, affordable clinical products in frontier biotechnology — the same capacity that positions India as a potential source of the next major cancer breakthrough.
India's Biomedical Research Ecosystem and Policy Framework
India's cancer research infrastructure has expanded significantly over the past decade, anchored by premier institutions such as Tata Memorial Centre (Mumbai), All India Institute of Medical Sciences (Delhi), ICMR-National Centre for Disease Informatics and Research (NCDIR), and IITs entering translational biomedical research. The Government of India has supported this through policy measures including full GST exemption on gene therapy products (announced December 2024, effective January 2025), funding under the National Biopharma Mission, and the Rashtriya Arogya Nidhi for rare disease treatment. The ICMR-NCRP, operational since 1981, provides the epidemiological data backbone — tracking cancer incidence across population-based and hospital-based registries.
- ICMR-NCDIR (Bengaluru) runs India's National Cancer Registry Programme since 1981.
- Estimated 1.46 million new cancer cases in India in 2022; projected 1.57 million for 2025.
- Leading cancer sites: digestive system cancers, breast, genital system, oral cavity/pharynx, respiratory system.
- GST exemption for gene therapy: notified December 2024, effective January 2025.
- National Biopharma Mission (2017): ₹1,500 crore to accelerate biopharmaceutical development.
Connection to this news: The combination of a large patient population (providing trial scale), cost-competitive manufacturing, top-tier research institutions, and supportive policy creates the ecosystem conditions for breakthrough cancer research to emerge from India.
Medical Innovation and India's Broader S&T Ambitions
India's trajectory in medical innovation reflects a wider shift from being a generic drug manufacturer to a frontier innovator in healthcare. The same collaborative model that produced NexCAR19 — academia (IIT Bombay) + specialised hospital (Tata Memorial) + biotech startup (ImmunoACT) + government support — is being replicated across other disease areas. Bhabha Atomic Research Centre (BARC) has developed indigenous Ruthenium-106 plaques for eye cancer brachytherapy. Indian scientists are working on bi-specific 3rd-generation CAR-T therapies (Cellogen Therapeutics) and newer cancer targets beyond CD19. India's large and genetically diverse population also provides unique opportunities for cancer genomics and personalised medicine research.
- NexCAR19 development was seeded partly through collaboration with NIH's National Cancer Institute (NCI), USA.
- Government of India exempted gene therapy from GST in January 2025 to lower treatment costs further.
- India's pharmaceutical sector is the world's third largest by volume, positioning it for scale-up in biotech.
- The National Policy for Rare Diseases (2021) provides financial assistance up to ₹50 lakh for certain gene therapy treatments.
- India's science and technology policy (STI Policy 2020 draft) emphasises translational research and deep-tech startups.
Connection to this news: India's demonstrated capability in CAR-T therapy is a proof of concept that the country can produce globally significant biomedical innovations — not just affordable generics — placing it as a credible candidate for the next cancer treatment breakthrough.
Key Facts & Data
- NexCAR19: India's first indigenous CAR-T cell therapy; developed by IIT Bombay + Tata Memorial Centre + ImmunoACT
- CDSCO approval: October 2023; Presidential launch: April 2024
- Target antigen: CD19 (B-cell lymphoma and leukaemia)
- Clinical trial response rate: 67% objective response in 64 patients; ~50% complete remission
- Indian price: ~₹40 lakh (~$50,000) vs ~$400,000 in the United States
- ICMR-NCRP projected cancer cases: 1.46 million (2022), 1.57 million (2025)
- GST exemption on gene therapy products: effective January 2025
- Second approved CAR-T therapy in India: Qartemi (Immuneel Therapeutics)
- BARC-developed Ruthenium-106 plaques: indigenous eye cancer brachytherapy tool